Vanda Pharmaceuticals (STU:VM4) Cash Flow for Lease Financing : €0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Cash Flow for Lease Financing?

Vanda Pharmaceuticals's Cash Flow for Lease Financing for the three months ended in Mar. 2025 was €0.0 Mil. Vanda Pharmaceuticals's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Dec. 2024 ), Vanda Pharmaceuticals's Cash Flow for Lease Financing remained the same in Mar. 2025 (€0.0 Mil).

Vanda Pharmaceuticals Cash Flow for Lease Financing Historical Data

The historical data trend for Vanda Pharmaceuticals's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Cash Flow for Lease Financing Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Flow for Lease Financing

Get a 7-Day Free Trial

Vanda Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash Flow for Lease Financing	Get a 7-Day Free Trial															-	-	-	-	-

Vanda Pharmaceuticals Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.

Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Vanda Pharmaceuticals Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » Cash Flow for Lease Financing

Comparable Companies

Traded in Other Exchanges

VNDA:USA 0LKB:UK VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals Headlines

No Headlines